中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与被动化疗对比(HIVEC-II):一项2期开放标签随机对照试验
HIVEC-II是一项在15个中心开展的2期开放标签随机对照试验,2014年5月至2017年12月纳入259例中危非肌层浸润性膀胱癌患者,1:1随机接受43°C丝裂霉素C热化疗或室温丝裂霉素C化疗。24个月无病生存率热化疗组61%对对照组60%(HR 0.92,95%CI 0.62-1.37;P=0.8),热化疗组治疗完成率较低(59%对89%),不良事件以低级别为主。作者结论为不推荐热化疗优于单纯化疗。
要点
- 24个月无病生存率热化疗组61%对对照组60%,无显著差异(HR 0.92,95%CI 0.62-1.37;P=0.8)。
- 意向性分析中对照组无进展生存更高(HR 3.44,95%CI 1.09-10.82;P=0.02),符合方案分析未达显著(HR 2.87,95%CI 0.83-9.98;P=0.06)。
- 热化疗组治疗完成率59%对对照组89%,III级不良事件热化疗组13例对对照组7例。
核心结论
- 对于中危非肌层浸润性膀胱癌,不推荐膀胱内热化疗优于单纯化疗。
- 热化疗后不良事件为低级别且短暂,但患者治疗完成率较低。
研究设计与样本
- HIVEC-II为开放标签、2期随机对照试验,2014年5月至2017年12月在15个中心招募中危非肌层浸润性膀胱癌患者(ISRCTN 23639415)。
- 按治疗医院分层随机,1:1分配至43°C丝裂霉素C热化疗组或室温丝裂霉素C对照组,共259例(热化疗组131例对对照组128例)。
- 两组均接受每周6次40 mg丝裂霉素C灌注,每次持续60分钟。
- 主要终点为经膀胱镜和尿细胞学确定的24个月无病生存,按意向性分析。
主要发现
- 24个月时热化疗组42例(32%)出现复发,对照组49例(38%)出现复发。
- 24个月无病生存率热化疗组61%(95%CI 51-69%)对对照组60%(95%CI 50-68%)(HR 0.92,95%CI 0.62-1.37;log-rank P=0.8)。
- 意向性分析中对照组无进展生存更高(HR 3.44,95%CI 1.09-10.82;log-rank P=0.02),符合方案分析未达统计学显著(HR 2.87,95%CI 0.83-9.98;log-rank P=0.06)。
- 总生存两组相似(HR 2.55,95%CI 0.77-8.40;log-rank P=0.09)。
- 热化疗组治疗完成率较低(75例,59%对111例,89%);164例报告不良事件(热化疗组87例对对照组77例),III级不良事件少见(热化疗组13例对对照组7例)。
关键数值与推荐
- 中危非肌层浸润性膀胱癌肿瘤切除后推荐辅助膀胱内化疗。
- 热化疗组24个月无病生存率61%(95%CI 51-69%)对对照组60%(95%CI 50-68%),HR 0.92(95%CI 0.62-1.37),log-rank P=0.8。
- 意向性分析无进展生存HR 3.44(95%CI 1.09-10.82),log-rank P=0.02,对照组更高;符合方案分析HR 2.87(95%CI 0.83-9.98),log-rank P=0.06。
- 总生存HR 2.55(95%CI 0.77-8.40),log-rank P=0.09。
- 两组均接受每周6次40 mg丝裂霉素C灌注60分钟;热化疗组温度43°C。
临床怎么用
- 作者结论认为,对于中危非肌层浸润性膀胱癌,不能推荐热化疗优于单纯化疗。
- 热化疗后不良事件为低级别且短暂,但患者治疗完成率较低(59%对89%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant intravesical chemotherapy following tumour resection is recommended for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). OBJECTIVE: To assess the efficacy and safety of adjuvant intravesical chemohyperthermia (CHT) for intermediate-risk NMIBC. DESIGN, SETTING, AND PARTICIPANTS: HIVEC-II is an open-label, phase 2 randomised controlled trial of CHT versus chemotherapy alone in patients with intermediate-risk NMIBC recruited at 15 centres between May 2014 and December 2017 (ISRCTN 23639415). Randomisation was stratified by treating hospital. INTERVENTIONS: Patients were randomly assigned (1:1) to adjuvant CHT with mitomycin C at 43°C or to room-temperature mitomycin C (control). Both treatment arms received six weekly instillations of 40 mg of mitomycin C lasting for 60 min. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was 24-mo disease-free survival as determined via cystoscopy and urinary cytology. Analysis was by intention to treat. RESULTS: A total of 259 patients (131 CHT vs 128 control) were randomised. At 24 mo, 42 patients (32%) in the CHT group and 49 (38%) in the control group had experienced recurrence. Disease-free survival at 24 mo was 61% (95% confidence interval [CI] 51-69%) in the CHT arm and 60% (95% CI 50-68%) in the control arm (hazard ratio [HR] 0.92, 95% CI 0.62-1.37; log-rank p = 0.8). Progression-free survival was higher in the control arm (HR 3.44, 95% CI 1.09-10.82; log-rank p = 0.02) on intention-to-treat analysis but was not significantly higher on per-protocol analysis (HR 2.87, 95% CI 0.83-9.98; log-rank p = 0.06). Overall survival was similar (HR 2.55, 95% CI 0.77-8.40; log-rank p = 0.09). Patients undergoing CHT were less likely to complete their treatment (n =75, 59% vs n = 111, 89%). Adverse events were reported by 164 patients (87 CHT vs 77 control). Major (grade III) adverse events were rare (13 CHT vs 7 control). CONCLUSIONS: CHT cannot be recommended over chemotherapy alone for intermediate-risk NMIBC. Adverse events following CHT were of low grade and short-lived, although patients were less likely to complete their treatment. PATIENT SUMMARY: The HIVEC-II trial investigated the role of heated chemotherapy instillations in the bladder for treatment of intermediate-risk non-muscle-invasive bladder cancer. We found no cancer control benefit from heated chemotherapy instillations over room-temperature chemotherapy. Adverse events following heated chemotherapy were low grade and short-lived, although these patients were less likely to complete their treatment.
引用
- Tan WS, Prendergast A, Ackerman C, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. 2022. PMID: 35999119. doi:10.1016/j.eururo.2022.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。